Etribnabdione BID
Phase 2Small molecule
Etribnabdione BID is one of 34 small molecule programs targeting Peripheral Arterial Disease. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
39 competitors in Peripheral Arterial Disease
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Plavix
SanofiApproved
Brilinta
AstraZenecaApproved
Praluent
RegeneronApproved
Zyloprim
Jazz PharmaceuticalsApproved
Colcrys
Jazz PharmaceuticalsApproved
Zetia
OOrganon and Co
Approved
Pletal
OtsukaApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Torisel
PPrism Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Etribnabdione BID. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- VVivaCell Biotechnology España